ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 65.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,618 shares of the biopharmaceutical company’s stock after selling 80,007 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in ACADIA Pharmaceuticals were worth $764,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. Barclays PLC raised its holdings in ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after buying an additional 154,854 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in ACADIA Pharmaceuticals during the 3rd quarter worth about $483,000. Burney Co. acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter worth about $6,953,000. Finally, BNP Paribas Financial Markets raised its holdings in ACADIA Pharmaceuticals by 259.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after buying an additional 161,331 shares during the period. 96.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. StockNews.com downgraded ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $23.00 to $20.00 in a report on Friday, January 3rd. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Trading Down 1.7 %

Shares of ACAD opened at $19.95 on Monday. ACADIA Pharmaceuticals Inc. has a 1 year low of $14.15 and a 1 year high of $26.56. The stock has a market cap of $3.32 billion, a P/E ratio of 25.58 and a beta of 0.37. The stock’s 50-day moving average price is $18.20 and its two-hundred day moving average price is $16.73.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.